Across TCGA pan-cancer cohorts, ARL17B RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated ARL17B data layer.
The strongest signal is observed in mesothelioma (MESO), where higher ARL17B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL17B expression acts as an unfavorable survival marker, although some lineages such as READ and GBM show a favorable association.
MESO, LUSC, and ACC are the cancer types where ARL17B RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.